IRIS
FORCONI, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.218
EU - Europa 7.520
AS - Asia 4.562
SA - Sud America 1.064
AF - Africa 289
Continente sconosciuto - Info sul continente non disponibili 165
OC - Oceania 12
Totale 27.830
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.081
CN - Cina 1.689
GB - Regno Unito 1.671
RU - Federazione Russa 1.291
SG - Singapore 1.227
IE - Irlanda 1.008
IT - Italia 1.000
BR - Brasile 863
UA - Ucraina 819
FR - Francia 521
SE - Svezia 446
HK - Hong Kong 439
VN - Vietnam 427
DE - Germania 348
KR - Corea 267
FI - Finlandia 220
ZA - Sudafrica 186
BD - Bangladesh 134
IN - India 84
AR - Argentina 59
CA - Canada 56
EC - Ecuador 43
MX - Messico 42
TR - Turchia 40
IQ - Iraq 39
NL - Olanda 30
NG - Nigeria 28
PK - Pakistan 28
ID - Indonesia 25
AT - Austria 23
PL - Polonia 23
VE - Venezuela 23
JP - Giappone 21
UZ - Uzbekistan 21
ES - Italia 20
CO - Colombia 19
PY - Paraguay 17
SA - Arabia Saudita 17
MA - Marocco 16
CL - Cile 15
BE - Belgio 14
AU - Australia 12
IL - Israele 11
KE - Kenya 11
AE - Emirati Arabi Uniti 10
CZ - Repubblica Ceca 10
EU - Europa 10
LT - Lituania 10
PH - Filippine 10
EG - Egitto 9
HR - Croazia 9
JO - Giordania 9
TN - Tunisia 9
UY - Uruguay 9
GR - Grecia 8
MY - Malesia 8
PE - Perù 8
TT - Trinidad e Tobago 8
AZ - Azerbaigian 7
DZ - Algeria 7
JM - Giamaica 7
AL - Albania 6
BO - Bolivia 6
CI - Costa d'Avorio 5
ET - Etiopia 5
NP - Nepal 5
OM - Oman 5
PT - Portogallo 5
TH - Thailandia 5
BA - Bosnia-Erzegovina 4
CH - Svizzera 4
CR - Costa Rica 4
GT - Guatemala 4
HN - Honduras 4
IR - Iran 4
KG - Kirghizistan 4
LU - Lussemburgo 4
PA - Panama 4
PS - Palestinian Territory 4
RO - Romania 4
SN - Senegal 4
BG - Bulgaria 3
KZ - Kazakistan 3
LV - Lettonia 3
MD - Moldavia 3
SY - Repubblica araba siriana 3
AM - Armenia 2
AO - Angola 2
BH - Bahrain 2
DK - Danimarca 2
EE - Estonia 2
GE - Georgia 2
GY - Guiana 2
KH - Cambogia 2
MK - Macedonia 2
MM - Myanmar 2
QA - Qatar 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
AI - Anguilla 1
Totale 27.654
Salva come PNG Salva come JPEG
Città #
Fairfield 2.212
Southend 1.468
Ashburn 1.225
Dallas 1.127
Woodbridge 1.012
Dublin 1.004
Seattle 902
Houston 783
Wilmington 763
Cambridge 732
Singapore 662
Jacksonville 660
Santa Clara 569
Chandler 555
Hong Kong 432
Moscow 406
Ann Arbor 366
Beijing 359
Milan 354
Hefei 293
Seoul 264
San Jose 240
Princeton 223
Nanjing 214
Siena 202
Council Bluffs 199
The Dalles 179
Johannesburg 167
Ho Chi Minh City 146
Lauterbourg 123
Los Angeles 115
Rome 106
Hanoi 92
San Diego 87
Columbus 80
Nanchang 80
Boardman 79
São Paulo 75
Helsinki 73
Buffalo 72
New York 61
Shenyang 61
Redondo Beach 45
London 44
San Mateo 40
Hebei 39
Rio de Janeiro 37
Changsha 35
Shanghai 34
Jiaxing 31
Norwalk 30
San Francisco 30
Dong Ket 29
Orem 29
Da Nang 28
Frankfurt am Main 28
Tianjin 28
Abuja 27
Chicago 27
Kunming 27
Figino 25
Flanders 25
Toronto 25
Turin 24
Bengaluru 23
Falls Church 23
Menlo Park 23
Düsseldorf 22
Ningbo 22
Belo Horizonte 21
Brasília 21
Zhengzhou 21
Nuremberg 20
Tashkent 20
Brooklyn 19
Jinan 18
Curitiba 17
Guayaquil 17
Hangzhou 17
Philadelphia 17
Tokyo 17
Guangzhou 16
Haiphong 16
Munich 16
Warsaw 16
Florence 15
Naples 15
Mexico City 14
Phoenix 14
Baghdad 13
Dhaka 13
Quito 13
Boston 12
Brussels 12
Cape Town 12
Goiânia 12
Montreal 12
Washington 12
Lappeenranta 11
Porto Alegre 11
Totale 20.102
Salva come PNG Salva come JPEG
Nome #
13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia 331
A P210-derived multipeptide vaccine (CMLVAX100) induces reduction of “stable” minimal residual disease in chronic myeloid leukemia (CML) patients during treatment with Imatinib or alpha-Interferon 317
A pilot monocentric analysis of efficacy and safety of Fludarabine-Campath combination (Flucam) as first line treatment in elderly patients with chronic lymphocytic leukaemia and Tp53 disfunction 296
BRAF mutations in hairy-cell leukemia 278
Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis 276
2-Chlorodeoxyadenosine in the treatment of relapsed/refractory chronic lymphoproliferative disorders 270
B-cell receptor, clinical course and prognosis in chronic lymphocytic leukaemia: the growing saga of the IGHV3 subgroup gene usage 260
Selective influences in the expressed immunoglobulin heavy and light chain gene repertoire in hairy cell leukemia. 256
Alternative methods of cladribine administration 254
Overlapping morphologic and immunophenotypic profiles in small B-cell lymphoma. A report of two cases. 250
Insight into the behavior of hairy cell leukemia by immunogenetic analysis 248
Impaired expression of p66Shc, a novel regulator of B-cell survival, in chronic lymphocytic leukemia 246
Angiopoietin-2 plasma dosage predicts time to first treatment and overall survival in chronic lymphocytic leukemia 242
A variant of the LRP4 gene affects the risk of chronic lymphocytic leukaemia transformation to Richter syndrome 240
Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia 240
The IGHV1-69/IGHJ3 recombinations of unmutated CLL are distinct from those of normal B cells 240
S1P1 expression is controlled by the pro-oxidant activity of p66Shc and is impaired in B-CLL patients with unfavorable prognosis 236
The SF3B1 inhibitor spliceostatin A (SSA) elicits apoptosis in chronic lymphocytic leukaemia cells through downregulation of Mcl-1 230
Imatinib does not impair specific antitumor T-cell immunity in patients with chronic myeloid leukemia 230
Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosis 230
Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia 230
Emerging drugs in chronic myelogenous leukaemia 227
Lack of allelic exclusion by secondary rearrangements of tumour B-cell receptor light chains in hairy cell leukaemia 227
Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma 227
Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia 225
Absence of surface CD27 distinguishes hairy cell leukemia from other leukemic B-cell malignancies 224
Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia 224
The host genetic background of DNA repair mechanisms is an independent predictor of survival in diffuse large B-cell lymphoma 222
Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia 222
Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation 222
Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. 222
Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness 220
The normal IGHV1-69-derived B-cell repertoire contains stereotypic patterns characteristic of unmutated CLL 219
Molecular cytogenetic analysis of B-CLL patients with aggressive disease 219
Genetics and prognostication in splenic marginal zone lymphoma: Revelations from deep sequencing 218
Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation 217
Multicentre validation of a prognostic index for overall survival in chronic lymphocytic leukaemia 216
Molecular insight into the biology and clinical course of hairy cell leukemia utilizing immunoglobulin gene analysis 214
Genome-wide DNA analysis identifies recurrent imbalances predicting outcome in chronic lymphocytic leukaemia with 17p deletion 212
Towards the pharmacotherapy of hairy cell leukaemia 212
CD30 positive (non-anaplastic) peripheral T-cell lymphoma of the thyroid gland 212
The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation 212
IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia 210
Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes 210
IGHD3-3 fails to behave as unfavourable prognostic marker in chronic lymphocytic leukaemia 209
Molecular and clinical features of chronic lymphocytic leukemia with stereotyped B-cell receptors in a Ukrainian cohort 208
Expression of mutated IGHV3-23 genes in chronic lymphocytic leukemia identifies a disease subset with peculiar clinical and biological features 208
Thrombotic thrombocytopenic purpura secondary to an occult adenocarcinoma 207
Impact of the host genetic background on prognosis of chronic lymphocytic leukemia 207
Molecular prediction of durable remission after first-line fludarabinecyclophosphamide-rituximab in chronic lymphocytic leukemia 207
The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness 207
Are surrogates of IGHV gene mutational status useful in B-cell chronic lymphocytic leukemia? The example of Septin-10 206
Molecular history of Richter syndrome: origin from a cell already present at the time of chronic lymphocytic leukemia diagnosis 206
Integrated DNA copy number and methylation profiling of lymphoid neoplasms using a single array 206
Stimulation of surface IgM of chronic lymphocytic leukemia cells induces an unfolded protein response dependent on BTK and SYK 203
The coexistence of chronic lymphocytic leukemia and myeloproliperative neoplasms: a retrospective multicentric GIMEMA experience 203
Pilot study of gemtuzumab ozogamicin (GO), fludarabine, cytarabine and idarubicin combined regimen (GO-FLAI) as first-line induction therapy plus GO alone as consolidation therapy for elderly acute myeloid leukemia patients. 202
Low-dose oral fludarabine plus cyclophosphamide in elderly patients with chronic lymphoproliferative disorders. 201
Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior. 201
Genome-wide DNA profiling better defines the prognosis of chronic lymphocytic leukaemia 198
Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome 198
Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence 198
Predicting the clinical course of Hodgkin lymphoma 198
Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study 198
MDM4 (MDMX) is overexpressed in chronic lymphocytic leukaemia (CLL) and marks a subset of p53wild-type CLL with a poor cytotoxic response to Nutlin-3 196
Bcr-abl peptides for chronic myeloid leukemia. 195
HLA-G is a component of the chronic lymphocytic leukemia escape repertoire to generate immune suppression: Impact of the HLA-G 14 base pair (rs66554220) polymorphism 194
Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study 194
Trisomy 12 and t(14;22)(q32;q11) in a patient with B-cell chronic lymphocytic leukemia 192
Complete molecular remission induced by concomitant cladribine--rituximab treatment in a case of multi-resistant hairy cell leukemia 191
Engagement of the B-cell receptor of chronic lymphocytic leukemia cells drives global and MYC-specific mRNA translation 189
Insight into the potential for DNA idiotypic fusion vaccines designed for patients by analysing xenogeneic anti-idiotypic antibody responses 188
Variant B cell receptor isotype functions differ in hairy cell leukemia with mutated BRAF and IGHV genes 186
Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance 186
Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia 185
Revisiting the definition of somatic mutational status in B-cell tumors: does 98% homology mean that a V(H)-gene is unmutated? 184
High density genome-wide DNA profiling reveals a remarkably stable profile in hairy cell leukaemia 184
BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib 181
Origins of the malignant clone in typical Waldenstrom's macroglobulinemia 181
Low-dose oral fludarabine plus cyclophosphamide in elderly patients with untreated and relapsed or refractory chronic lymphocytic Leukaemia 181
IL-4 enhances expression and function of surface IgM in CLL cells 180
Endothelin-1 promotes survival and chemoresistance in chronic lymphocytic leukemia B cells through eta receptor 180
The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia 179
Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome 177
Phenotypic heterogeneity in IGHV-mutated CLL patients has prognostic impact and identifies a subset with increased sensitivity to BTK and PI3Kδ inhibition 176
Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome 175
STING activation reverses lymphoma-mediated resistance to antibody immunotherapy 175
Hairy cell leukaemia: biological and clinical overview from immunogenetic insights 175
V-H and V-L genes in hairy cell leukemia reveal a dynamic on-going modification of the surface B-cell receptor 175
Large genomic aberrations detected by SNP array are independent prognosticators of a shorter time to first treatment in chronic lymphocytic leukemia patients with normal FISH 174
The Meaning and Relevance of B-Cell Receptor Structure and Function in Chronic Lymphocytic Leukemia 171
The outcome of B-cell receptor signaling in chronic lymphocytic leukemia: Proliferation or anergy 171
Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia 171
Genomic profiling of Richter's syndrome: recurrent lesions and differences with de novo diffuse large B-cell lymphomas 170
Endothelium-mediated survival of leukemic cells and angiogenesis-related factors are affected by lenalidomide treatment in chronic lymphocytic leukemia 170
Tumor cells of hairy cell leukemia express multiple clonally related immunoglobulin isotypes via RNA splicing 169
Hairy cell leukemia cell lines expressing annexin A1 and displaying B-cell receptor signals characteristic of primary tumor cells lack the signature BRAF mutation to reveal unrepresentative origins. 169
Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide 169
Comprehensive characterization of IGHV3-21-expressing B-cell chronic lymphocytic leukemia: an Italian multicenter study 167
The outcome of Chronic lymphocytic leukaemia patients with 97% IGHV gene identity to germline is distinct from cases with <97% identity and similar to those with 98% identity 167
Totale 20.971
Salva come PNG Salva come JPEG
Categoria #
all - tutte 84.120
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 84.120
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.456 0 261 50 96 71 54 86 49 87 194 165 343
2022/20232.071 156 118 308 288 217 441 33 154 241 24 57 34
2023/20241.289 67 32 66 121 30 374 448 6 7 16 9 113
2024/20253.341 89 173 218 156 455 203 73 208 274 149 313 1.030
2025/20267.480 629 1.267 876 823 1.030 301 650 324 260 330 265 725
2026/2027469 403 66 0 0 0 0 0 0 0 0 0 0
Totale 27.830